-
2 weeks ago | 
insidehealthpolicy.com | Gabrielle Wanneh |Donna Haseley
The Justice Department and Federal Trade Commission’s plan to hold a July 24 listening session on formulary and benefit barriers that keep drug prices high could coincide with a potential move by FTC to jump-start its stalled case against top pharmacy benefit managers.
-
1 month ago | 
insidehealthpolicy.com | Donna Haseley
In just 100 days the U.S. health care system has been turned on its head, leaving industry stakeholders who thrive on certainty reeling from the ensuing regulatory unpredictability and wondering whether the system they’ve navigated for decades will return.
-
2 months ago | 
insidehealthpolicy.com | Maaisha Osman |Donna Haseley
HHS Secretary Robert F. Kennedy Jr. doubled down on his calls for a radical transformation of government health agencies, telling FDA staff Friday ( April 11) the agency has become a “sock puppet” of the industries it regulates and urging them to resist the “deep state,” according to a recording obtained by media outlets, capping off a tumultuous week that included a key public health group’s call for Kennedy’s resignation and a duo of Journal of the American Medical Association...
-
Feb 18, 2025 | 
insidehealthpolicy.com | Jessica Karins |Amy Lotven |Christian Robles |Donna Haseley
The Trump administration fired thousands probationary employees at HHS and its subagencies over the weekend apparently without regard to the programs they worked on, adding to widespread uncertainty among health care stakeholders about how the new administration will handle everything from FDA user fees to the administration of Medicare and Medicaid. The cuts were condemned by former agency heads from the Biden administration Monday (Feb. 17).
-
Feb 12, 2025 | 
insidehealthpolicy.com | Donna Haseley |Maaisha Osman
President Donald Trump again referenced a desire to stop U.S. consumers from paying more for drugs than people overseas, specifically mentioning high U.S. prices for GLP-1s, in an interview during the Super Bowl that adds to confusion on what drug pricing policies he has in store. In the Monday (Feb. 10) interview, Trump promised to fix the situation without providing details other than a reference to his earlier support for drug imports, and he mentioned he might slap tariffs on...
-
Jan 17, 2025 | 
insidehealthpolicy.com | Gabrielle Wanneh |Donna Haseley
The Biden administration on Friday (Jan. 17) announced the 15 drugs -- which include GLP-1 diabetes drugs, cancer and asthma treatments -- it has selected for the next round of Medicare price negotiation, unveiling the list before the Feb. 1 deadline in an apparent attempt to shape the next round of price talks before the Trump administration takes over Monday (Jan. 20). The inclusion of GLP-1s on the list is significant because President Joe Biden’s CMS has proposed Medicare and...
-
Nov 27, 2024 | 
insidehealthpolicy.com | Charlie Mitchell |Donna Haseley
Moody’s Ratings finds that artificial intelligence will “improve clinical and administrative efficiencies” in health care by helping to address labor shortages, but also increases cybersecurity risks and poses regulatory challenges. “A new report from Moody’s Ratings finds that AI will benefit the healthcare sector, offering the potential to attract clinical staff and to improve clinical and administrative efficiencies.
-
Nov 26, 2024 | 
insidehealthpolicy.com | Sigi Ris |Donna Haseley
President-elect Trump’s new Department of Government Efficiency (DOGE) -- to be headed by Vivek Ramaswamy and Elon Musk -- could save $2.1 trillion over a decade by making changes to Medicaid and Medicare, Paragon Health Institute says. The group says the estimated savings would be hundreds of billions of dollars greater if they included reduced interest payments from lower spending and if the Congressional Budget Office updated its calculations of older proposals.
-
Nov 13, 2024 | 
insidehealthpolicy.com | Gabrielle Wanneh |Donna Haseley
Johnson & Johnson’s decision to sue HHS Tuesday (Nov. 12) for blocking the company’s plan to offer drug rebates instead of upfront discounts to 340B safety net hospitals could force the incoming Trump administration to quickly form a stance on the rebate model and other controversial issues surrounding the drug discount program.
-
Nov 11, 2024 | 
insidehealthpolicy.com | Donna Haseley |Maaisha Osman
The Pharmaceutical Research and Manufacturers of America (PhRMA ) is launching a major ad campaign pressing lawmakers to move forward on long-debated pharmacy benefit manager (PBM) reforms amid uncertainty over what will be included in a potential lame-duck health care package.
